October 10, 2017 09:36 AM EDT

Deerfield commits $50M-plus to translational drug R&D at the Broad

Shehla Shakoor

Managing Director

Deerfield Management and the famous Broad Institute of MIT and Harvard have come up with a novel plan for pursuing translational drug research work. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Deerfield commits $50M-plus to translational drug R&D at the Broad

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Deer­field com­mits $50M-plus to trans­la­tion­al drug R&D at the Broad

Managing Director

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Deerfield commits $50M-plus to translational drug R&D at the Broad